Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood–brain barrier permeability

Abstract

The clinical application of central nervous system (CNS) drugs is limited by their poor bioavailability due to the blood-brain barrier (BBB). Borneol is a naturally occurring compound in a class of 'orificeopening' agents often used for resuscitative purposes in traditional Chinese medicine. A growing body of evidence confirms that the 'orifice-opening' effect of borneol is principally derived from opening the BBB. Borneol is therefore believed to be an effective adjuvant that can improve drug delivery to the brain. The purpose of this paper is to provide a comprehensive review of information accumulated over the past two decades on borneol's chemical features, sources, toxic and kinetic profiles, enhancing effects on BBB permeability and their putative mechanisms, improvements in CNS drug delivery, and pharmaceutical forms. The BBB-opening effect of borneol is a reversible physiological process characterized by rapid and transient penetration of the BBB and highly specific brain regional distribution. Borneol also protects the structural integrity of the BBB against pathological damage. The enhancement of the BBB permeability is associated with the modulation of multiple ATP-binding cassette transporters, including P-glycoprotein; tight junction proteins; and predominant enhancement of vasodilatory neurotransmitters. Systemic co-administration with borneol improves drug delivery to the brain in a region-, dose-and time-dependent manner. Several pharmaceutical forms of borneol have been developed to improve the kinetic and toxic profiles of co-administered drugs and enhance their delivery to the brain. Borneol is a promising novel agent that deserves further development as a BBB permeation enhancer for CNS drug delivery. ARTICLE HISTORY

Proanthocyanidin B2 inhibits proliferation and induces apoptosis of osteosarcoma cells by suppressing the PI3K/AKT pathway

“…In the current studies, we thus conducted both in vitro and in vivo experiments delay gastric empty and prolong bowel transit time. 54,55 We will conduct clinical studies to further investigate whether PB2 assisted with…”

New Approaches for Cryptococcosis Treatment

“…The nanoparticles significantly increased ITC uptake by the bEnd.3 cells (a mouse brain cell line) and promoted~2-fold higher brain uptake in mice than ITC conventional formulation [115]. Borneol is a highly lipid-soluble bicyclic monoterpene that can facilitate penetration of drugs in the brain due to BBB opening [116]. Another study used a 29-amino-acid peptide derived from rabies virus glycoprotein (RVG29) conjugated with albumin nanoparticles as carrier for ITC (RVG29-ITC-NP), and demonstrated a significant drug accumulation in the brain compared to albumin nanoparticles without RVG29 and a cyclodextrin formulation of ITC [117].…”

Anticonvulsant Essential Oils and Their Relationship with Oxidative Stress in Epilepsy

“…Cao et al [154] demonstrated that borneol may be a novel therapeutic agent for fear and anxiety disorders. Wu et al [155] demonstrated that borneol increased blood-brain barrier permeability; related to increased ICAM-1 expression, thus becoming a promising candidate for treatment of brain tumors and infections, as well as chronic disorders in the central nervous system [155,156]. In an experimental model of permanent cerebral ischemia, borneol reduced the size of ischemia by decreasing expression of nitric oxide synthase and TNF-α in a dose-dependent manner [157].…”